
    
      Pilot clinical data suggest that recombinant human relaxin may be effective in treating
      patients with decompensated CHF. This study will randomize patients in blinded manner to one
      of two doses of intravenous relaxin or placebo. Serial evaluations will include cardiac and
      renal function, as well as safety and tolerability.
    
  